Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Reentry Medication topic
No spam. Unsubscribe anytime.
Lawmakers press DOC and Wellpath on medication continuity and Medicaid barriers at release
Summary
DOC and Wellpath staff told the committee that while most people leaving custody receive prescriptions or vouchers for an initial supply, challenges remain arranging community appointments, Medicaid re-enrollment and providing MAT continuity; committee discussed injectables to reduce immediate post-release overdose risk.
Legislators pressed DOC and Wellpath officials on Nov. 21 about whether people leaving detention consistently receive medications and a reliable bridge to community care.
Isaac Deo, policy director for DOC, and Wellpath medical staff described steps the department and its contractor take: for people on regular prescriptions, individuals may leave with up to a 28‑day supply and a prescription; Wellpath provides a voucher to cover the initial 30‑day pharmacy fill for many patients. DOC/Wellpath staff said they attempt to schedule intake appointments with community providers during pre-release planning — often 30 to 90 days before release — but availability of primary care and hub-and-spoke MAT capacity varies across the state.
On MAT, Wellpath’s medical presenters said not everyone is routed to a hub; the goal is to connect people with the most accessible community provider. Participants said MAT intake appointments are typically scheduled and accessible within about a week in most cases, though DOC staff cautioned that availability varies. The committee heard that for detainees released unexpectedly from court, DOC may lack capacity to complete prescheduled enrollment tasks and those people are more likely to face gaps in prescription and Medicaid coverage after release.
The committee discussed long‑acting injectable medications for opioid use disorder as an option to reduce the spike in overdose deaths immediately after release. As Isaac Deo put it, "the risk of death from untreated opioid use disorder in the first week after incarceration is astronomically high," and the committee heard injectables can offer a protective bridge but raise cost and logistics questions.
Committee members also asked who assists with Medicaid re-enrollment; Wellpath and DOC said staff provide enrollment support when possible but that rapid, unexpected releases and loss of benefit notices while incarcerated complicate the process.
Next steps: Committee members asked the agencies to clarify operational responsibilities in written materials and to coordinate with the working group and standing committees so statutory or contract language aligns with current practice.
